Magnesium, Partenium, Andrographis, Co-enzyme Q10 and Riboflavin (PACR) in Migraine Prophylaxis

Last updated: December 9, 2018
Sponsor: University of Roma La Sapienza
Overall Status: Active - Recruiting

Phase

N/A

Condition

Migraine (Adult)

Oral Facial Pain

Treatment

N/A

Clinical Study ID

NCT03190044
ParMig Study
  • Ages 18-65
  • All Genders

Study Summary

Migraine is a highly disabling disorder that affects hundreds of millions of people around the world. Yet, a little number of prophylactic treatments are available still now. The limited number of available drugs leads to a wide use of nutraceutical compounds in migraine therapy. To improve the efficacy, some of these nutraceuticals were combined. So far, we do not know if these combinations are really more effective than the single compounds alone, or an anti-synergic effect could be present because of a reciprocal antagonism of effects. For this reason, we decided to test the efficacy of a fixed combination of magnesium, partenium, andrographis, co-enzyme Q10 and riboflavin (PACR) as prophylactic treatment for migraine in a randomized controlled double blind study.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • diagnosis of migraine (with or without aura)

  • both genders

  • age between 18 and 65 y.o.

  • more than 1 year of migraine history

  • no other headache conditions

  • a migraine frequency between 2 and 8 per month

Exclusion

Exclusion Criteria:

  • Prophylactic treatments in the last 3 months

  • pregnancy or lactation

  • other medical conditions that requires a daily drug assumption

  • intolerance or allergic reactions to some of compounds of the product.

Study Design

Total Participants: 82
Study Start date:
June 06, 2017
Estimated Completion Date:
December 31, 2019

Connect with a study center

  • Policlinico Umberto I

    Rome, 00161
    Italy

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.